DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tracleer (Bosentan) - Published Studies

 
 



Tracleer Related Published Studies

Well-designed clinical trials related to Tracleer (Bosentan)

Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. [2014]

BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. [2011.07.01]

Rationale and design of a trial on the role of bosentan in Fontan patients: improvement of exercise capacity? [2011.07]

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. [2011.06]

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. [2011.01]

Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan. [2011]

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. [2010.09.28]

Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. [2010.07]

Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. [2010.07]

Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men. [2010.06]

Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. [2010.05]

Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. [2010.05]

A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. [2010.03.30]

Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. [2010.03]

Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). [2010.01]

Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. [2010.01]

Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. [2010]

Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men. [2010]

Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. [2010]

Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia. [2009.05]

Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude. [2009.02.28]

Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. [2009.02]

Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. [2009]

Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. [2008.12.16]

Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude. [2008.10.11]

Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. [2008.06.23]

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. [2008.06.21]

A randomized, controlled trial of bosentan in severe COPD. [2008.04.30]

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. [2008.01.01]

A Randomized Placebo-Controlled Trial of Bosentan in Patients with Idiopathic Pulmonary Fibrosis. [2007.09.27]

Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. [2007.06]

Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. [2007.03]

Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. [2007.01]

Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. [2006.12.01]

An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease. [2006.11]

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. [2006.07.04]

Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. [2006.03]

Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. [2005.10]

Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. [2005.10]

The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans. [2005.04]

Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. [2005.02]

Survival with first-line bosentan in patients with primary pulmonary hypertension. [2005.02]

Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects. [2005.01]

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. [2004.12]

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. [2004.09]

Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. [2003.04.16]

Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. [2003]

Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? [2002.10]

Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. [2002.06]

In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. [2002.04]

Bosentan therapy for pulmonary arterial hypertension. [2002.03.21]

Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. [2002.03]

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. [2001.10.06]

Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. [2000.07.25]

Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. [2000.01]

Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. [1999.08]

Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. [1999.07]

The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. [1999.06]

Protection against aspirin-induced human gastric mucosal injury by bosentan, a new endothelin-1 receptor antagonist. [1999.05]

Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. [1998.11.24]

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. [1998.03.19]

Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. [1997.01]

Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. [1996.10]

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. [1996.08]

Well-designed clinical trials possibly related to Tracleer (Bosentan)

Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations. [2014]

Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. [2012]

[Treatment of pulmonary fibrosis : New substances and new interventions.] [2011.11.19]

Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. [2011]

Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. [2010.10.29]

Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. [2010.10]

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. [2010.05.04]

Tadalafil: in pulmonary arterial hypertension. [2010.03.05]

Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans. [2010.03]

The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. [2010.02]

The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. [2010.01]

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. [2010]

Tadalafil: in pulmonary arterial hypertension. [2010]

The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. [2010]

No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. [2009.12]

Insights into the mechanisms and mediators of the effects of air pollution exposure on blood pressure and vascular function in healthy humans. [2009.09]

Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: A subgroup analysis. [2009.05.20]

Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: a qualitative systematic review. [2009.03]

Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. [2009]

Selective endothelin A-receptor blockade attenuates coronary microvascular dysfunction after coronary stenting in patients with type 2 diabetes. [2009]

Management of Pulmonary Arterial Hypertension Associated with Congenital Systemic-to-Pulmonary Shunts and Eisenmenger's Syndrome. [2008]

Treprostinil for pulmonary hypertension. [2008]

Evidence-based pharmacologic management of pulmonary arterial hypertension. [2007.10]

Does endothelin play a role in chemoreception during acute hypoxia in normal men? [2007.05]

Sitaxsentan for treatment of pulmonary hypertension. [2007.01]

Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. [2006.12]

Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. [2006.09.26]

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. [2006.05.16]

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. [2005.06.01]

[Emerging Therapies for the Treatment of Pulmonary Arterial Hypertension.] [2005.06]

Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure. [2004.06]

Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. [2000.04.15]

Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. [1999.06]

Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. [1998.11.24]

Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. [1995.09.16]

Other research related to Tracleer (Bosentan)

Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. [2013]

Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. [2012]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017